Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 163 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
New

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

for
Breast Cancer, Breast Carcinoma, Cancer of the Breast,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT07619534

Recruiting

Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer

for
Anatomic Stage II Breast Cancer AJCC v8,
Location: New Haven CT, Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: Female

Age: 40 - 65

Code: NCT06582615

Recruiting

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Cleveland OH, Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: Female

Age: 18+

Code: NCT05677802

Recruiting

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

for
Breast Cancer, Hereditary Breast and Ovarian Cancer
Location: Lee's Summit MO, Kansas City MO, Kansas City KS,
Sponsor: University of Kansas Medical Center

Sex: All

Age: 0+

Code: NCT02302742

Recruiting

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

for
Breast, Metastatic, Triple Negative, Cancer,
Location: Los Angeles CA
Sponsor: University of Southern California

Sex: All

Age: 18 - 70+

Code: NCT04333706

Phase1, Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence

for
Breast Cancer
Location: Montreal, Ottawa, London
Sponsor: Jewish General Hospital

Sex: All

Age: 18+

Code: NCT04874064

Recruiting

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: New York NY, Baltimore MD, Richmond VA, Aventura FL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT03606967

Phase2, Recruiting

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

for
Anatomic Stage III Breast Cancer AJCC v8,
Location: Boston MA, Mineola NY, New York NY, Columbus OH,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05422794

Phase1, Recruiting

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

for
Anatomic Stage III Breast Cancer AJCC v8,
Location: Atlanta GA
Sponsor: Emory University

Sex: Female

Age: 18+

Code: NCT05741164

Phase2, Recruiting

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Atlanta GA
Sponsor: Emory University

Sex: All

Age: 18+

Code: NCT06324240

Phase1, Recruiting

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

for
Breast Cancer
Location: Princeton NJ, Glen Burnie MD, Jacksonville FL,
Sponsor: Cellectar Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT07311993

Phase1, Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

for
Breast Neoplasms
Location: Westbrook ME, Burlington MA, New York NY,
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT07173751

Phase3, Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

for
Breast Neoplasms
Location: Boston MA, Sherbrooke, Westbury NY, White Plains NY,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT06926868

Phase2, Phase3, Recruiting

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

for
Anatomic Stage III Breast Cancer AJCC v8,
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute

Sex: All

Age: 18+

Code: NCT06434064

Phase2, Recruiting

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: Charlottesville VA, Buffalo NY
Sponsor: Roswell Park Cancer Institute

Sex: Female

Age: 18+

Code: NCT04348747

Phase2, Recruiting

The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy

for
Breast Neoplasms
Location: Baton Rouge LA
Sponsor: Pennington Biomedical Research Center

Sex: Female

Age: 18+

Code: NCT06318507

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

for
Breast Cancer
Location: Providence RI, New Haven CT, Quebec, Stony Brook NY,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06103864

Phase3, Recruiting

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: Los Angeles CA
Sponsor: Yuan Yuan

Sex: All

Age: 18+

Code: NCT05318469

Phase1, Phase2, Recruiting

Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer

for
Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III,
Location: London
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Sex: All

Age: 18+

Code: NCT07188246

Phase2, Recruiting

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

for
Triple Negative Locally Advanced Non-resectable Breast Cancer,
Location: Boston MA, Toronto, Columbus OH, Nashville TN,
Sponsor: Marengo Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06827613

Phase1, Phase2, Recruiting